Logotype for Sheela Foam Limited

Sheela Foam (SFL) Q3 24/25 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Sheela Foam Limited

Q3 24/25 earnings summary

19 Dec, 2025

Executive summary

  • Achieved strong topline and profitability growth in Q3 and 9M FY25, with consolidated Q3 EBITDA margin nearing double digits and robust B2C mattress volume growth at 24% YoY.

  • E-commerce and rural initiatives, including Tarang and Aaram brands, drove significant growth, making the company the second largest online mattress brand in India.

  • Integration of Kurlon acquisition is in final stages, with accounting closure expected within the financial year.

  • International business share declined as focus shifted to India, but Australia and Spain subsidiaries showed mixed performance and recovery.

  • Furlenco expanded its subscriber base, entered new cities, and the company increased its stake to 43.89%.

Financial highlights

  • Q3 FY25 consolidated revenue rose to INR 967.11 crore, up 10% YoY; EBITDA at INR 88 crore (+15% YoY); net profit at INR 18.59 crore, down from INR 31.17 crore in Q3 FY24.

  • Standalone Q3 revenue at INR 791 crore, up 54% YoY; EBITDA at INR 71 crore (+34% YoY); net profit at INR 25 crore, down 19% YoY.

  • 9M FY25 consolidated revenue at INR 2,590 crore (+21% YoY); EBITDA at INR 217 crore (-1% YoY); net profit at INR 75 crore, down 37% YoY.

  • Gross margin for Q3 FY25 consolidated at 40.6%; India business at 39.7%; Australia at 52.8%; Spain at 29.8%.

  • Total comprehensive loss for Q3 FY25 was INR 5.24 crore, mainly due to exchange differences on foreign operations.

Outlook and guidance

  • India mattress business expected to grow 18%-19% annually over the next 2-3 years, with EBITDA margins around 15%.

  • B2B segment anticipated to grow 8%-10% with consolidated EBITDA margins targeted at 12%-14% in three years.

  • Long-term EBITDA margin target for India business is 14%-15% by 2027.

  • Price hikes of 3%-5% announced for mattresses, effective February.

  • Ongoing amalgamation schemes are subject to regulatory approvals and have not yet been accounted for in the financials.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more